drugset / Trial / NCT02171533
Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
To investigate whether and to what extent the P-glycoprotein inhibitor (P-gp) verapamil affects the pharmacokinetic parameters of dabigatran with verapamil given at different dosages, in different formulations (immediate release (IR) and extended release (ER)), and in different intervals in relation to the dabigatran dose.
Timeline
- Start
- 2008-06
- Primary completion
- 2008-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran | Unknown | 150 mg | Oral |
| Subject | Verapamil | Other / unclassified | 120 mg | Oral |
| Subject | Verapamil | Other / unclassified | 240 mg | Oral |
| Subject | Verapamil | Other / unclassified | 480 mg | Oral |
Indications
No indication recorded.